HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

In vivo activity of evernimicin (SCH 27899) against methicillin-resistant Staphylococcus aureus in experimental infective endocarditis.

Abstract
Currently, there exist few satisfactory alternatives to vancomycin for therapy of serious methicillin-resistant Staphylococcus aureus (MRSA) infections. We employed a rat model of aortic valve endocarditis to assess the potential efficacy of evernimicin (SCH 27899) compared with vancomycin against infection with a strain susceptible to both agents (MICs of 0.25 and 0.50 microg/ml, respectively). Infected animals were assigned to one of three groups: controls (no treatment), evernimicin at 60 mg/kg of body weight by intravenous (i.v.) infusion once daily, or vancomycin at 150 mg/kg of body weight per day by continuous i.v. infusion. Therapy was administered for 5.5 days. At the start of therapy, colony counts in vegetations were 6.63 +/- 0.44 log(10) CFU/g. In both treatment groups, bacterial density within vegetations was significantly reduced in comparison with control animals that had not been treated. Final colony counts were as follows (mean +/- standard deviation): controls, 10.12 +/- 1.51 log(10) CFU/g of vegetation; evernimicin, 7.22 +/- 2.91 log(10) CFU/g of vegetation; vancomycin, 5.65 +/- 1.76 log(10) CFU/g of vegetation. The difference between the evernimicin and vancomycin groups was not significant. These results confirmed the bacteriostatic activity of evernimicin in vivo in an experimental model of severe MRSA infection.
AuthorsH W Boucher, C Thauvin-Eliopoulos, D Loebenberg, G M Eliopoulos
JournalAntimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 45 Issue 1 Pg. 208-11 (Jan 2001) ISSN: 0066-4804 [Print] UNITED STATES
PMID11120967 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Aminoglycosides
  • Anti-Bacterial Agents
  • evernimicin
  • Vancomycin
Topics
  • Aminoglycosides
  • Animals
  • Anti-Bacterial Agents (blood, therapeutic use)
  • Colony Count, Microbial
  • Endocarditis, Bacterial (drug therapy, microbiology)
  • Male
  • Methicillin Resistance
  • Rats
  • Rats, Sprague-Dawley
  • Staphylococcal Infections (drug therapy, microbiology)
  • Staphylococcus aureus (drug effects)
  • Treatment Outcome
  • Vancomycin (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: